Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373488 | 0.95 | S1PR1 (0.39) | NR3C1S1PR1S1PR3P2RX3NPBWR1 | |
| SCHEMBL12373637 | 0.88 | NR3C1 (0.41) | NR3C1S1PR1S1PR3P2RX3NPBWR1 | |
| SCHEMBL12373544 | 0.87 | PGR (0.41) | NR3C1S1PR1S1PR3 | |
| SCHEMBL12373551 | 0.87 | CCR4 (0.39) | NR3C1S1PR1S1PR3SLC40A1NPBWR1 | |
| SCHEMBL12373547 | 0.87 | PGR (0.40) | NR3C1S1PR1S1PR3P2RX3NPBWR1 | |
| SCHEMBL12373579 | 0.87 | S1PR1 (0.40) | NR3C1S1PR1S1PR3NPBWR1MCHR1 | |
| SCHEMBL12373631 | 0.86 | KAT6A (0.38) | S1PR1S1PR3P2RX3 | |
| SCHEMBL12373702 | 0.85 | CCR4 (0.39) | S1PR1S1PR3SLC40A1 | |
| SCHEMBL12373563 | 0.85 | S1PR1 (0.35) | S1PR1S1PR3P2RX3 | |
| SCHEMBL12373686 | 0.85 | S1PR1 (0.37) | S1PR1S1PR3P2RX3NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | NR3C1 165/4885S1PR1 1/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.